Physician profile
Joseph Krill
NPI 1154741064
$36,523.06
in general payments reported to CMS, 2019-2025
41 companies · $2,074 in 2025
The $2,074 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $967 · 2020: $110 · 2021: $26K · 2022: $2,024 · 2023: $2,344 · 2024: $3,054 · 2025: $2,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,290 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,289.78 |
| Education | $182.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $26,049.58 | 2019-2024 | Resolution 360 Clip |
| Abbvie INC. | $2,051.51 | 2020-2025 | |
| Janssen Biotech, INC. | $933.62 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.03 | 2020-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $658.36 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $633.98 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $580.11 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $514.17 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $434.28 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $363.65 | 2021-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $329.26 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $316.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $301.05 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $237.23 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $218.90 | 2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $214.23 | 2023-2025 | Accrufer |
| Pfizer INC. | $195.06 | 2021-2025 | |
| Genzyme Corporation | $190.01 | 2023-2025 | |
| Redhill Biopharma INC. | $188.06 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Aimmune Therapeutics, INC. | $185.99 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $167.95 | 2024-2025 | Vegzelma, Zymfentra |
| Novo Nordisk INC | $131.59 | 2022-2025 | Wegovy |
| Aries Pharmaceuticals, INC. | $100.45 | 2019 | |
| Ironwood Pharmaceuticals, INC | $95.70 | 2024 | |
| Nestle Healthcare Nutrition INC. | $90.18 | 2021-2022 | |
| Braintree Laboratories, INC. | $80.37 | 2022-2025 | Sutab, Suflave |
| Ambu INC. | $74.77 | 2021 | |
| Echosens North America, INC. | $66.82 | 2025 | Fibroscan |
| Merck Sharp & Dohme LLC | $56.93 | 2024 | Dificid |
| Endogastric Solutions, INC | $50.03 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $41.12 | 2023 | Fujifilm |
| Evoke Pharma, INC. | $37.95 | 2021-2023 | Gimoti |
| Alcresta Therapeutics, INC. | $37.52 | 2023 | Relizorb |
| Medtronic, INC. | $36.91 | 2023-2024 | Gi Genius |
| Shionogi INC | $36.76 | 2019 | |
| Apollo Endosurgery US INC | $34.54 | 2021 | |
| Shire North American Group INC | $31.43 | 2019 | |
| Olympus America INC. | $20.56 | 2024 | Endoclot Sis |
| Exact Sciences Corporation | $17.88 | 2023 | Cologuard Collection Kit |
| Vibrant Gastro, INC. | $17.23 | 2023 | Vibrant Starter Kit |
| Mallinckrodt Hospital Products INC. | $15.92 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Krill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.